How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
66
CHGCF Quote, Financials, Valuation and Earnings
Last price:
$57.95
Seasonality move
:
10.47%
Day range:
$55.85 - $57.95
52-week range:
$38.76 - $72.30
Dividend yield:
1.38%
P/E ratio:
32.91x
P/S ratio:
11.34x
P/B ratio:
7.38x
Volume:
1.8K
Avg. volume:
1.7K
1-year change:
27.76%
Market cap:
$95.4B
Revenue:
$8.4B
EPS (TTM):
$1.76
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
$57.95 | -- | $95.4B | 32.91x | $0.94 | 1.38% | 11.34x |
|
HLOSF
Healios KK
|
$2.10 | -- | $242.4M | -- | $0.00 | 0% | 329.74x |
|
PPTDF
PeptiDream Inc.
|
$10.42 | -- | $1.3B | 13.79x | $0.00 | 0% | 11.22x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.44 | -- | $492.3M | -- | $0.00 | 0% | 2.54x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
-- | -1.345 | -- | 3.46x |
|
HLOSF
Healios KK
|
47.23% | -0.193 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.074 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.070 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
$1.7B | $1.1B | 22.41% | 22.53% | 48.92% | $560.8M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Chugai Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns CHGCF or HLOSF?
Healios KK has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.74.72% $0.51 $12.9B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About CHGCF or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is CHGCF or HLOSF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.091, which suggesting that the stock is 109.099% less volatile than S&P 500. In comparison Healios KK has a beta of 0.262, suggesting its less volatile than the S&P 500 by 73.819%.
-
Which is a Better Dividend Stock CHGCF or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.94 per share corresponding to a yield of 1.38%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 103.14% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHGCF or HLOSF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Healios KK quarterly revenues of $128.8K. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Healios KK's net income of $3.8M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.91x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.34x versus 329.74x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.34x 32.91x $2.2B $833.4M HLOSFHealios KK329.74x -- $128.8K $3.8M
-
Which has Higher Returns CHGCF or PPTDF?
PeptiDream Inc. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -25.38%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.74.72% $0.51 $12.9B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is CHGCF or PPTDF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.091, which suggesting that the stock is 109.099% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.666%.
-
Which is a Better Dividend Stock CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.94 per share corresponding to a yield of 1.38%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 103.14% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.91x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.34x versus 11.22x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.34x 32.91x $2.2B $833.4M PPTDFPeptiDream Inc.11.22x 13.79x $29.3M -$7.4M
-
Which has Higher Returns CHGCF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -24.76%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.74.72% $0.51 $12.9B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is CHGCF or SOLTF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.091, which suggesting that the stock is 109.099% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.018, suggesting its less volatile than the S&P 500 by 98.16%.
-
Which is a Better Dividend Stock CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.94 per share corresponding to a yield of 1.38%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 103.14% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.91x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.34x versus 2.54x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.34x 32.91x $2.2B $833.4M SOLTFNxera Pharma Co., Ltd.2.54x -- $45.8M -$11.3M
-
Which has Higher Returns CHGCF or STMM?
Stemcell Holdings, Inc. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of --. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.74.72% $0.51 $12.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is CHGCF or STMM More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.091, which suggesting that the stock is 109.099% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.94 per share corresponding to a yield of 1.38%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 103.14% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 32.91x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.34x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.34x 32.91x $2.2B $833.4M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Alerts
Buy
73
ENPH alert for Feb 5
Enphase Energy, Inc. [ENPH] is up 38.57% over the past day.
Sell
1
PYPL alert for Feb 4
PayPal Holdings, Inc. [PYPL] is down 1.61% over the past day.
Sell
44
SHNY alert for Feb 4
MicroSectors Gold 3X Leveraged ETN [SHNY] is up 0.3% over the past day.
